(Q36021635)

English

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

6

object named as

Linda T Vahdat

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

author name string

Alexander N Starodub

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Allyson J Ocean

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Manish A Shah

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Michael J Guarino

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Vincent J Picozzi

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Sajeve S Thomas

7

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Serengulam V Govindan

8

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Pius P Maliakal

9

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

William A Wegener

10

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Steven A Hamburger

11

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Robert M Sharkey

12

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

David M Goldenberg

13

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

language of work or name

0 references

publication date

5 May 2015

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

21

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

17

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

3870-3878

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Trop-2 is a determinant of breast cancer survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

2 October 2017

Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

2 October 2017

Antibody-drug conjugates in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

2 October 2017

Upregulation of Trop-2 quantitatively stimulates human cancer growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

2 October 2017

Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

2 October 2017

CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

2 October 2017

Trop2: a possible therapeutic target for late stage epithelial carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

2 October 2017

Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

2 October 2017

Clinical pharmacokinetics and metabolism of irinotecan (CPT-11).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

2 October 2017

Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

11 July 2018

Brentuximab vedotin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

23 September 2018

Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4558321

23 September 2018

Letter to the Editor: Efficacy and safety of anti-Trop antibodies, R. Cubas, M. Li, C. Chen and Q. Yao, Biochim Biophys Acta 1796 (2009) 309–1

1 reference

https://pubmed.ncbi.nlm.nih.gov/25944802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/25944802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-14-3321

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36021635&oldid=1987523377"